Literature DB >> 2007710

Effect of lesion characteristics on outcome of directional coronary atherectomy.

T Hinohara1, M H Rowe, G C Robertson, M R Selmon, L Braden, J H Leggett, J W Vetter, J B Simpson.   

Abstract

Directional coronary atherectomy, a new transluminal procedure for treatment of obstructive lesions in coronary arteries by excision and removal of tissue, was performed on 447 lesions in 382 procedures. Successful outcome, defined as a reduction of stenosis by greater than or equal to 20% with a less than 50% residual stenosis, was achieved in 89.5% of lesions and mean stenosis was reduced from 75.9 +/- 13.3% to 14.5 +/- 22.1% (p less than 0.001). Complications included vessel occlusion during the procedure, 2.4%; vessel occlusion after the procedure, 1.3%; new lesion, 0.5%; nonobstructive guiding catheter-induced dissection, 0.3%; perforation, 0.8%; distal embolization, 2.1%; Q wave myocardial infarction, 0.8% and non-Q wave myocardial infarction, 4.2%. Twelve patients (3.1%) required coronary artery bypass surgery for these complications. The atherectomy success rate was greater than 80% and the combined atherectomy and angioplasty success rate was greater than 90% for complex morphologic features such as eccentric lesions, lengthy lesions, lesions with abnormal contour, angulated lesions, ostial lesions and lesions with branch involvement. In the presence of calcific deposition, atherectomy success rate was 52% for primary lesions and 83% for restenosed lesions. Among angiographically complex lesions, calcium was the predictor for failed atherectomy (p less than 0.0001). In summary, directional coronary atherectomy is safe and effective for treatment of obstructive lesions in coronary arteries in selected cases. In particular, it achieves a high success rate in lesions with complex morphologic characteristics, such as eccentricity, abnormal contour and ostial involvement.

Entities:  

Mesh:

Year:  1991        PMID: 2007710     DOI: 10.1016/0735-1097(91)90840-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Surgical cover for percutaneous transluminal coronary angioplasty. The Council of the British Cardiovascular Intervention Society.

Authors: 
Journal:  Br Heart J       Date:  1992-09

2.  Intravascular ultrasound imaging for guidance of atherectomy and other plaque removal techniques.

Authors:  P G Yock; P J Fitzgerald; K Sudhir; D T Linker; W White; A Ports
Journal:  Int J Card Imaging       Date:  1991

3.  Directional atherectomy facilitates the interventional procedure and leads to a low rate of recurrent stenosis in left anterior descending and left circumflex artery ostium stenoses: subgroup analysis of the FLEXI-CUT study.

Authors:  J B Dahm; J Ruppert; S Hartmann; D Vogelgesang; A Hummel; S B Felix
Journal:  Heart       Date:  2006-01-31       Impact factor: 5.994

4.  Quantified frequency-domain optical coherence tomography analysis for the thin-high signals on restenotic tissue after paclitaxel-coated balloon angioplasty.

Authors:  Hideyuki Kawashima; Nobuaki Suzuki; Taiga Katayama; Shinji Takahashi; Ryuta Okabe; Shintaro Takamura; Yusuke Watanabe; Hiroyuki Kyono; Ken Kozuma
Journal:  Heart Vessels       Date:  2017-12-16       Impact factor: 2.037

5.  Histopathological examination of specimens removed during directional coronary atherectomy in patients presenting with crescendo angina show mural thrombus.

Authors:  C M Bellamy; E D Grech; M T Ashworth; D R Ramsdale
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

Review 6.  Restenosis following coronary angioplasty: current status.

Authors:  M K Hong
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

7.  Percutaneous transluminal coronary angioplasty for coronary artery stenosis in a young patient with long term Kawasaki Disease.

Authors:  Seok In Hong; Pum Joon Kim; Ki Bae Seung; Jung Hyun Kwon; Ju Yeal Beak; Chang Dong Yeo; Kyu Bo Choi
Journal:  Korean J Intern Med       Date:  2005-06       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.